Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma

Bone Marrow Transplantation
G VassalO Hartmann

Abstract

Repeated high-dose (HD) chemotherapy with peripheral blood stem cell (PBSC) transplantation is a new modality aimed at increasing both the dose and its intensity in the treatment of chemosensitive tumours. The aim of this study was to evaluate the tolerance, pharmacokinetics (PK) and pharmacodynamics (PD) of HD single-agent melphalan administered over two consecutive courses (C1 and C2) in children. Twenty-one patients (10 girls) with a median age of 4.1 years (range 8 months-14 years) were entered into this study. Five had metastatic neuroblastoma (NB) and 16 a cerebral primitive neuroectodermal tumour (PNET). Melphalan was given at a dose of 100 mg/m(2) every 21 days. PBSCs were infused at a median number of 2.98 x 10(6) CD34(+) cells/kg. Forty courses, ie 21 C1 and 19 C2, were administered. Both courses were well tolerated. The median duration of ANC < 500/microl was 7 and 6 days after C1 and C2, respectively. Platelet recovery (not mandatory to continue the HD strategy) was achieved in 52% of courses. GI toxicity was mild to moderate. The melphalan AUC ranged from 177 to 475 microg small middle dotmin/ml (no difference between C1 and C2). Prolonged neutropenia was associated with a young age (P < 0.001) and a low amount of ...Continue Reading

References

Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D Y PloinC Ardiet
Jul 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H S FriedmanE C Halperin
Feb 1, 1988·American Journal of Clinical Oncology·M C ChamberlainV A Levin
Jan 1, 1989·Cancer Chemotherapy and Pharmacology·B TranchandC Ardiet
Jan 1, 1986·Cancer Chemotherapy and Pharmacology·A GouyetteJ L Pico
Aug 1, 1981·Journal of Pharmacokinetics and Biopharmaceutics·L B Sheiner, S L Beal
Jul 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B L Samuels, J D Bitran
Aug 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G M BrodeurF Hedborg
Sep 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S I BearmanG B McDonald
Oct 6, 1997·Bone Marrow Transplantation·S JagannathB Barlogie
May 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C AghajanianD R Spriggs

❮ Previous
Next ❯

Citations

Feb 3, 2011·European Journal of Clinical Pharmacology·Francesco BellantiOscar Della Pasqua
Aug 8, 2007·Bone Marrow Transplantation·C E NathL Zeng
Feb 9, 2012·International Journal of Surgical Oncology·Christelle DufourJacques Grill
Mar 26, 2003·Medical and Pediatric Oncology·Carlos Rodriguez-GalindoAlberto S Pappo
Feb 28, 2007·British Journal of Clinical Pharmacology·Christa E NathJohn W Earl
Jun 25, 2010·British Journal of Clinical Pharmacology·Christa E NathJohn Earl
Aug 2, 2005·The Lancet Oncology·Jacques GrillUNKNOWN French Society of Paediatric Oncology
Nov 3, 2016·Experimental Animals·Tomoyuki AbeYutaka Hanazono
Aug 19, 2014·Bone Marrow Transplantation·P J ShawH M Lazarus

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.